(5Z)-7-Oxozeaenol: Selective TAK1 Inhibitor for Inflammation Research

Executive Summary: (5Z)-7-Oxozeaenol is a resorcylic lactone that acts as a highly selective, irreversible inhibitor of transforming growth factor β-activated kinase 1 (TAK1) with an IC₅₀ of 8.1 nM in biochemical assays (product information). It effectively blocks interleukin-1-induced TAK1 activity and downstream NF-κB and JNK/p38 MAPK signaling in cell-based systems at 500 nM, 17.5 hours incubation. Topical administration in animal models reduces picryl chloride-induced ear swelling by up to 50%, supporting its use in inflammation research. (5Z)-7-Oxozeaenol is a valuable tool for delineating the roles of TAK1 in metabolic stress adaptation and inflammatory responses (Autophagy 2024). Compared to previous reviews (TAK1 Inhibitor Workflows), this article integrates new mechanistic insights linking TAK1 to AMPK-SQSTM1 feedback under metabolic stress.

Biological Rationale

TAK1 (MAP3K7) is a mitogen-activated protein kinase kinase kinase involved in transmitting pro-inflammatory and stress signals downstream of cytokines like interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α). TAK1 activation leads to the engagement of key transcription factors, including NF-κB and the JNK/p38 MAPK branches, which regulate inflammatory gene expression and cellular adaptation to stress (Autophagy 2024). Recent studies have highlighted TAK1's role in phosphorylating SQSTM1/p62, linking inflammatory signaling to the regulation of metabolic stress responses and antioxidant defense through AMPK and NFE2L2/NRF2 activation (AMPK–SQSTM1 Feedback Loop). Selective TAK1 inhibition thus offers a precise means to dissect these pathways, particularly in the context of inflammation and metabolic adaptation in cancer cells.

Mechanism of Action of (5Z)-7-Oxozeaenol

(5Z)-7-Oxozeaenol is a naturally occurring resorcylic lactone derived from fungal sources. It covalently and irreversibly inhibits TAK1 kinase activity by targeting the ATP-binding pocket, conferring nanomolar potency (IC₅₀ ≈ 8.1 nM) against purified TAK1 with minimal off-target effects on other MAPKKKs (APExBIO product page). Upon TAK1 inhibition, downstream activation of NF-κB and JNK/p38 MAPK is suppressed, resulting in decreased expression of pro-inflammatory mediators such as cyclooxygenase-2 (COX-2). This blockade also impairs TAK1-mediated phosphorylation of SQSTM1/p62, disrupting the feedback between metabolic stress and antioxidant defense (Autophagy 2024).

Evidence & Benchmarks

• (5Z)-7-Oxozeaenol inhibits TAK1 with an IC₅₀ of 8.1 nM in cell-free kinase assays (APExBIO product information).
• At 500 nM and 17.5 hours incubation, TAK1 and associated kinases are effectively blocked in IL-1-stimulated cell culture models (TAK1 Inhibitor Workflows).
• Selective TAK1 inhibition by (5Z)-7-Oxozeaenol results in strong suppression of NF-κB and JNK/p38 MAPK signaling, with minimal activity against related kinases (APExBIO).
• Topical dosing in picryl chloride-induced murine ear inflammation models reduces swelling by up to 50%, demonstrating robust in vivo efficacy (APExBIO).
• TAK1 phosphorylation of SQSTM1 at S24 and S226 is necessary for dual activation of AMPK and NFE2L2 during metabolic stress (Autophagy 2024).

This article extends prior overviews (TAK1 Inhibitor Workflows) by integrating recent mechanistic findings linking TAK1 to AMPK–SQSTM1 feedback loops in metabolic stress contexts.

Applications, Limits & Misconceptions

(5Z)-7-Oxozeaenol is primarily used as a tool compound in basic and translational research to dissect TAK1-dependent inflammatory and metabolic signaling. Its applications include:

• Modeling acute and chronic inflammation in vitro and in vivo.
• Dissecting NF-κB and JNK/p38 MAPK pathway contributions to disease phenotypes.
• Investigating metabolic adaptation in cancer cells, especially relating to AMPK–SQSTM1–NFE2L2 feedback (see Strategic TAK1 Inhibition for translational context).

Common Pitfalls or Misconceptions

• Not all MAPKKKs are equally inhibited: (5Z)-7-Oxozeaenol shows high selectivity for TAK1, with poor activity against related MAPKKKs (APExBIO).
• It is not suitable for long-term solution storage; solutions should be freshly prepared and used promptly (APExBIO).
• Solubility is limited in ethanol but effective in DMSO up to 9.06 mg/ml; improper solvent use leads to precipitation.
• In vivo efficacy is model-dependent; results from murine ear swelling models may not generalize to all inflammation paradigms.
• Does not inhibit downstream kinases directly; its effects are contingent on TAK1 pathway dependency.

Workflow Integration & Parameters

Protocol Parameters

• TAK1 inhibition in cell culture: Use 500 nM (5Z)-7-Oxozeaenol, pre-incubate for 17.5 hours prior to IL-1 stimulation.
• In vivo inflammation model: Apply topically in PC-induced murine ear swelling models; monitor for up to 50% reduction in edema.
• Solubility: Dissolve in DMSO at concentrations up to 9.06 mg/ml; avoid ethanol as a vehicle due to insolubility.
• Storage: Store as a desiccated solid at -20°C; avoid long-term storage of dissolved solutions.
• Shipping: Ship with blue ice packs for stability (APExBIO).

Refer to the APExBIO product page for detailed handling and safety instructions.

Conclusion & Outlook

(5Z)-7-Oxozeaenol, as supplied by APExBIO, is a benchmark TAK1 inhibitor with proven selectivity and efficacy in both cell-based and animal inflammation models. Its use has illuminated the critical role of TAK1 in linking inflammatory signaling to metabolic stress adaptation via AMPK–SQSTM1 feedback mechanisms (Autophagy 2024). Ongoing research will further clarify the therapeutic implications of targeting TAK1 in diseases characterized by chronic inflammation and metabolic dysregulation. For more on the evolving landscape, see AMPK–SQSTM1 Double Feedback, which this article updates by emphasizing the practical deployment and limits of (5Z)-7-Oxozeaenol as an experimental tool.